Abstract: This invention provides a method for treating Parkinson's disease (PD), particularly early stage of PD by orally administering to a mammal sporoderm-broken germination activated Ganoderma lucidum spore powders (GASP) to reduce and/or release the symptom of rotatory behavior in PD, to reduce the progression of neuron apoptosis and to improve the tyrosine hydroxylase (TH) activity so as to increase the conversion of hydroxydopamine (DOPA) to dopamine in the dopaminergic neurons. This invention also provides a method for reducing neuron apoptosis and a method for improving TH activity in dopaminergic neurons by orally administering to a mammal GASP.
Type:
Grant
Filed:
May 5, 2005
Date of Patent:
April 15, 2008
Assignee:
Enhan Technology Holdings International Co., Ltd.
Abstract: The present invention provides a method for treating patients with spinal cord injury by administering germination activated Ganoderma lucidium spores (GASP) to the patients. The GASP are sporoderm-broken. The GASP promote axon regeneration and improve motor neuron survival in the injured spinal cord.
Type:
Grant
Filed:
August 1, 2003
Date of Patent:
November 7, 2006
Assignee:
Enhan Technology Holdings International Co., Ltd.
Abstract: The present invention provides a method for treating patients with spinal cord injury by administering germination activated Ganoderma lucidium spores (GASP) to the patients. The GASP are sporoderm-broken. The GASP promote axon regeneration and improve motor neuron survival in the injured spinal cord.
Type:
Application
Filed:
August 1, 2003
Publication date:
February 3, 2005
Applicant:
Enhan Technology Holdings International Co., Ltd.